year 16, Issue 1 (January - February 2022)                   Iran J Med Microbiol 2022, 16(1): 76-82 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammed S H, Ahmed M M, Abd Alameer Abd Alredaa N, Haider Abd Alabbas H, Mohammad Ali Z D, Abed Al-Wahab Z Z, et al . Prevalence of Acinetobacter Species Isolated from Clinical Samples Referred to Al-Kafeel Hospital, Iraq and Their Antibiotic Susceptibility Patterns from 2017-2021. Iran J Med Microbiol. 2022; 16 (1) :76-82
URL: http://ijmm.ir/article-1-1377-en.html
1- Department of Clinical Laboratories, College of Applied Medical Sciences, Kerbala University, Kerbala, Iraq , shm.med.school@gmail.com
2- Department of Microbiology, College of Medicine, Kerbala University, Kerbala, Iraq
3- Department of Clinical Laboratories, College of Applied Medical Sciences, Kerbala University, Kerbala, Iraq
Abstract:   (601 Views)

Background and Objective: Acinetobacter has been considered an important nosocomial pathogen since 1970. This study aims to investigate the prevalence of Acinetobacter infection during 2017-2021, study the antibiogram of these bacteria, and study the impact of gender on infection.
Materials and Methods: This is a retrospective study in which data of the clinical samples received in Al-Kafeel Hospital, Kerbala, Iraq, between April 2017 and February 2021 were searched for Acinetobacter infection and their antibiotic susceptibility testing.
Results: The prevalence of Acinetobacter infection was 9.2% of cases. Male to Female ratio was 3:1, and there was a significant difference in Acinetobacter infection regarding gender. There were high resistance rates to major antibiotic classes. Maximum resistance was recorded for Amoxicillin (100%), followed by 3rd generation cephalosporins, including Cefotaxime (92.3%), Ceftriaxone (91.6%), Ceftazidime (91.3%), Cefixime (80%); in addition to growing resistance to carbapenems, Imipenem (42.8%) and Meropenem (62.2%). The lowest resistance rates were found to colistin sulfate (10%). There 80.7% of the isolates were multidrug-resistant MDR.
Conclusion: Acinetobacter spp., is considered as fast emerging opportunistic agents with evolving drug resistance. Rationale use of antibiotics is important and necessary to prevent microbial resistance. Gender is considered a risk factor for Acinetobacter infection.

Full-Text [PDF 447 kb]   (243 Downloads) |   |   Full-Text (HTML)  (236 Views)  
Type of Study: Original Research Article | Subject: Medical Bacteriology
Received: 2021/07/1 | Accepted: 2022/01/3 | ePublished: 2022/01/20

References
1. Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R. The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017. Antimicrob Resist Infect Control [Internet]. 2020;9(1):89. Available from: [DOI:10.1186/s13756-020-00750-5] [PMID] [PMCID]
2. Atrouni A Al, Joly-Guillou ML, Hamze M, Kempf M. Reservoirs of non-baumannii Acinetobacter species. Front Microbiol. 2016;7(FEB):1-12. [DOI:10.3389/fmicb.2016.00049] [PMID] [PMCID]
3. Shamsizadeh Z, Nikaeen M, Esfahani BN, Mirhoseini SH, Hatamzadeh M, Hassanzadeh A. Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: potential sources for transmission of Acinetobacter infections. Environ Health Prev Med. 2017;22(1):1-7. [DOI:10.1186/s12199-017-0653-4] [PMID] [PMCID]
4. Forster DH, Daschner FD. Acinetobacter species as nosocomial pathogens. Eur J Clin Microbiol Infect Dis. 1998;17(2):73-7. https://doi.org/10.1007/s100960050020 [DOI:10.1007/BF01682159]
5. Abdulzahra AT, Khalil MAF, Elkhatib WF. First report of colistin resistance among carbapenem-resistant Acinetobacter baumannii isolates recovered from hospitalized patients in Egypt. New microbes new Infect. 2018;26:53-8. [DOI:10.1016/j.nmni.2018.08.007] [PMID] [PMCID]
6. McDonald LC, Banerjee SN, Jarvis WR, System NNIS. Seasonal variation of Acinetobacter infections: 1987-1996. Clin Infect Dis. 1999;29(5):1133-7. [DOI:10.1086/313441] [PMID]
7. Spellberg B, Bonomo RA. "Airborne assault": a new dimension in Acinetobacter baumannii transmission. Crit Care Med. 2013;41(8). [DOI:10.1097/CCM.0b013e31829136c3] [PMID] [PMCID]
8. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2009;1103150282.
9. Rossau R, Van Landschoot A, Gillis M, De Ley J. Taxonomy of Moraxellaceae fam. nov., a new bacterial family to accommodate the genera Moraxella, Acinetobacter, and Psychrobacter and related organisms. Int J Syst Evol Microbiol. 1991;41(2):310-9. [DOI:10.1099/00207713-41-2-310]
10. Dijkshoorn L, van der Toorn J. Acinetobacter species: which do we mean? Clin Infect Dis. 1992;15(4):748-9. [DOI:10.1093/clind/15.4.748] [PMID]
11. Visca P, Seifert H, Towner KJ. Acinetobacter infection - An emerging threat to human health. IUBMB Life. 2011;63(12):1048-54. https://doi.org/10.1002/iub.534 [DOI:10.1002/iub.600] [PMID]
12. Munier A-L, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay J-L, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179-84. [DOI:10.1016/j.ijid.2018.11.371] [PMID]
13. Oberoi A, Aggarwal A, Lal M. A Decade of an Underestimated Nosocomal Pathogen-Acinetobacter In a Tertiary Care Hospital in Punjab. JK Sci. 2009;11(1).
14. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939-51. [DOI:10.1038/nrmicro1789] [PMID]
15. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol. 2007;28(3):293-8. [DOI:10.1086/512629] [PMID]
16. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-49. [DOI:10.1016/S1473-3099(10)70049-9]
17. Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, et al. Correction: Peroxisome proliferator-activated receptor (PPAR) α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med. 2018;215(6):1765. [DOI:10.1084/jem.2006183905142018c] [PMID] [PMCID]
18. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38. [DOI:10.1038/nri.2016.90] [PMID]
19. Voskuhl R. Sex differences in autoimmune diseases. Biol Sex Differ. 2011;2(1):1-21. [DOI:10.1186/2042-6410-2-1] [PMID] [PMCID]
20. Scotland RS, Stables MJ, Madalli S, Watson P, Gilroy DW. Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood, J Am Soc Hematol. 2011;118(22):5918-27. [DOI:10.1182/blood-2011-03-340281] [PMID] [PMCID]
21. Abid S, Xie S, Bose M, Shaul PW, Terada LS, Brody SL, et al. 17β-estradiol dysregulates innate immune responses to Pseudomonas aeruginosa respiratory infection and is modulated by estrogen receptor antagonism. Infect Immun. 2017;85(10):e00422-17. [DOI:10.1128/IAI.00422-17] [PMID] [PMCID]
22. Vermillion MS, Ursin RL, Attreed SE, Klein SL. Estriol reduces pulmonary immune cell recruitment and inflammation to protect female mice from severe influenza. Endocrinology. 2018;159(9):3306-20. [DOI:10.1210/en.2018-00486] [PMID] [PMCID]
23. Lone R, Shah A, Kadri SM, Lone S, Faisal S. Nosocomial multi-drug-resistant Acinetobacter infections-clinical findings, risk factors and demographic characteristics. Bangladesh J Med Microbiol. 2009;3(1):34-8. [DOI:10.3329/bjmm.v3i1.2969]
24. Gupta N, Gandham N, Jadhav S, Mishra RN. Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. J Nat Sci Biol Med. 2015;6(1):159-62. [DOI:10.4103/0976-9668.149116] [PMID] [PMCID]
25. Bhattacharyya S, Bhattacharyya I, Rit K, Mukhopadhyay PK, Dey JB, Ganguly U, et al. Antibiogram of Acinetobacter spp. isolated from various clinical specimens in a tertiary care hospital in West Bengal, India. Biomed Res. 2013;24(1).
26. Jain AL, Harding CM, Assani K, Shrestha CL, Haga M, Leber A, et al. Characteristics of invasive Acinetobacter species isolates recovered in a pediatric academic center. BMC Infect Dis. 2016;16(1):1-9. [DOI:10.1186/s12879-016-1678-9] [PMID] [PMCID]
27. Poirel L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life. 2011;63(12):1061-7. [DOI:10.1002/iub.532] [PMID]
28. Sadiq Z, Sehlawi A. Isolation and Identification of Acinetobacter baumannii Clinical Isolates using Novel Methods. J Babylon Univ. 2014;22(3).
29. AL-Baroody HN, Al-Ghanimi AAK. Isolation and Identification of Nosocomial Pathogen Acinetobacter baumannii From Al-Hussien Medical City in Karbala. Sci J Med Res. 2020;4(14):54-9.
30. Lahiri KK, Mani NS, Purai SS. Acinetobacter spp as nosocomial pathogen: Clinical significance and antimicrobial sensitivity. Med J Armed Forces India. 2004;60(1):7-10. [DOI:10.1016/S0377-1237(04)80148-5]
31. Hejnar P, Kolář M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of ss-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Biomed Pap. 1999;
32. Yadav SK, Bhujel R, Hamal P, Mishra SK, Sharma S, Sherchand JB. Burden of multidrug-resistant Acinetobacter baumannii infection in hospitalized patients in a tertiary care hospital of Nepal. Infect Drug Resist. 2020;13:725-32. [DOI:10.2147/IDR.S239514] [PMID] [PMCID]
33. Patel RV, Shah JS, Revathi G, Siika W, Shah R. Acinetobacter infections: a retrospective study to determine inhospital mortality rate and clinical factors associated with mortality. Infect Prev Pract [Internet]. 2019;1(2):100010. Available from: [DOI:10.1016/j.infpip.2019.100010] [PMID] [PMCID]
34. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why? Clin Infect Dis. 2015;61(11):1708-14. [DOI:10.1093/cid/civ576] [PMID]
35. Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. Jama. 2020;323(15):1478-87. [DOI:10.1001/jama.2020.2717] [PMID] [PMCID]
36. Neubeiser A, Bonsignore M, Tafelski S, Alefelder C, Schwegmann K, Rüden H, et al. Mortality attributable to hospital acquired infections with multidrug-resistant bacteria in a large group of German hospitals. J Infect Public Health. 2020;13(2):204-10. [DOI:10.1016/j.jiph.2019.07.025] [PMID]
37. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254-63. [DOI:10.1086/529198] [PMID]
38. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539. [DOI:10.3389/fmicb.2019.00539] [PMID] [PMCID]
39. Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 2018;62(1):e01631-17. [DOI:10.1128/AAC.01631-17]
40. Kong BH, Hanifah YA, Yusof MYM, Thong KL. Antimicrobial susceptibility profiling and genomic diversity of multidrug-resistant Acinetobacter baumannii isolates from a teaching hospital in Malaysia. Jpn J Infect Dis. 2011;64(4):337-40.
41. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471-84. [DOI:10.1128/AAC.01464-06] [PMID] [PMCID]
42. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291. [DOI:10.4103/0974-777X.68538] [PMID] [PMCID]
43. Ahmed MU, Farooq R, Al Hawashim N, Ahmed M, Yiannakou N, Sayeed F, et al. Sensitive, resistant and multi-drug resistant Acinetobacter baumanii at Saudi Arabia hospital eastern region. Pak J Pharm Sci. 2015;28(3).

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc